Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Enceph…

BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...
Science Daily

Study identifies neuronal basis of impaired consciousness in 'absence' epilepsy

Imagine slipping in and out of consciousness hundreds of times per day, staying awake the whole time but having no sense of awareness during these lapses. In children with absence epilepsy, these ...
Business Wire

Cavion’s T-Type Calcium Channel Modulator CX-8998 is Superior to Current Standard of Care in Suppressing Absence Seizures in a Genetic Epilepsy Model

CHARLOTTESVILLE, Va. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cavion, Inc., a clinical stage biotechnology company developing novel therapeutics for neurological diseases, announced today that their first ...
Nasdaq

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist.
News Medical

What Can We Learn from EEG’s of Patient’s with Epilepsy?

Epilepsy is a neurological condition characterised by recurrent episodes of seizures. Most cases of epilepsy do not have a clear cause. The primary pathogenesis of many forms of epilepsy is an ...
Healio

First seizure clinic provides visit, pediatric epilepsy diagnosis in less than a week

The first seizure clinic model enabled rapid diagnosis and treatment for children with epilepsy, according to data presented ...
EurekAlert!

Study identifies neuronal basis of impaired consciousness in ‘absence’ epilepsy

New Haven, Conn. — Imagine slipping in and out of consciousness hundreds of times per day, staying awake the whole time but having no sense of awareness during these lapses. In children with absence ...
Seeking Alpha

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic ...

NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (DRUG), a biotechnology company focused on developing novel therapies for neurological and ...